Table 2.
Treatment patterns of the initial post-discharge anticoagulant treatment received within 3 months after discharge among CAT patients with ≥ 3 months of follow-up after discharge and ≥ 3 months of follow-up after initiation of the outpatient treatment (n = 2243)
| Total N = 2243 |
DOACs N = 1300 | LMWH N = 526 | Warfarin N = 408 | UFH N = 6 |
Thrombolytic therapy N = 3 |
|
|---|---|---|---|---|---|---|
| Patients with discontinuation within 3 months of treatment initiationa(n,%) | 523 (23.3%) | 159 (12.2%) | 247 (47.0%) | 70 (17.2%) | 3 (50.0%) | 3 (100.0%) |
| Persistence to therapyat 3 months after treatment initiationb(n,%) | 1720 (76.7%) | 1141 (87.8%) | 279 (53.0%) | 338 (82.8%) | 3 (50.0%) | 0 (0.0%) |
| MPRc, mean ± SD | 0.9 (0.1) | 0.9 (0.1) | 0.9 (0.2) | 0.9 (0.1) | 0.4 (0.3) | 1.0 (0.0) |
| Adherence (MPR ≥ 0.80; n, %) | 1923 (85.7%) | 1154 (88.8%) | 402 (76.4%) | 363 (89.0%) | 0 (0.0%) | 3 (100.0%) |
1631 patients did not have evidence of anticoagulant treatment within 3 months after discharge; 1467 patients had outpatient anticoagulant therapy, but had less than 3 months of follow-up after outpatient treatment initiation.
aDiscontinuation is defined as a gap of > 60 days between end of days' supply for a prescription to the next dispensing date of a drug in the same treatment group, or as a switch to a new treatment group. Last date of days’ supply before this gap is the discontinuation date
bPersistence to therapy is defined as remaining on therapy with no gaps > 60 days between the end of days’ supply for a prescription to the next fill date of any drug in the same treatment group
cMPR is defined as the sum of days’ supply for all claims prior to the discontinuation date (i.e., while a patient is on therapy)